These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020 [TBL] [Abstract][Full Text] [Related]
25. Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update. Laurelli G; Falcone F; Gallo MS; Scala F; Losito S; Granata V; Cascella M; Greggi S Int J Gynecol Cancer; 2016 Nov; 26(9):1650-1657. PubMed ID: 27654262 [TBL] [Abstract][Full Text] [Related]
26. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Heinemann K; Reed S; Moehner S; Minh TD Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350 [TBL] [Abstract][Full Text] [Related]
27. Predictive Accuracy of Progesterone Receptor B in Young Women with Atypical Endometrial Hyperplasia and Early Endometrial Cancer Treated with Hysteroscopic Resection plus LNG-IUD Insertion. Raffone A; Travaglino A; Zullo FM; Gencarelli A; Micheli M; Miranda S; De Franciscis P; Insabato L; Di Spiezio Sardo A; Zullo F; Bifulco G J Minim Invasive Gynecol; 2021 Jun; 28(6):1244-1253. PubMed ID: 33122144 [TBL] [Abstract][Full Text] [Related]
28. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Andersson K; Batar I; Rybo G Contraception; 1992 Dec; 46(6):575-84. PubMed ID: 1493717 [TBL] [Abstract][Full Text] [Related]
29. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia. Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315 [TBL] [Abstract][Full Text] [Related]
30. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Sturridge F; Guillebaud J Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696 [TBL] [Abstract][Full Text] [Related]
31. Impact of the levonorgestrel-releasing intrauterine device on controlled ovarian stimulation outcomes. Adeleye AJ; Aghajanova L; Kao CN; Cedars MI; Sauer MV Fertil Steril; 2018 Jul; 110(1):83-88. PubMed ID: 29885884 [TBL] [Abstract][Full Text] [Related]
32. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662 [TBL] [Abstract][Full Text] [Related]
33. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. Zhou H; Cao D; Yang J; Shen K; Lang J Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472 [TBL] [Abstract][Full Text] [Related]
34. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs. Chi IC Contraception; 1991 Dec; 44(6):573-88. PubMed ID: 1773615 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958 [TBL] [Abstract][Full Text] [Related]
36. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review. Peng H; Jiang J; Li X Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856 [TBL] [Abstract][Full Text] [Related]
37. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785 [TBL] [Abstract][Full Text] [Related]
38. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ. Gu Z; Zhu P; Luo H; Zhu X; Zhang G; Wu S Contraception; 1995 Jul; 52(1):57-61. PubMed ID: 8521716 [TBL] [Abstract][Full Text] [Related]
39. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Pronin SM; Novikova OV; Andreeva JY; Novikova EG Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126 [TBL] [Abstract][Full Text] [Related]
40. Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments. Yin J; Ma S; Shan Y; Wang Y; Li Y; Jin Y; Pan L Cancer Prev Res (Phila); 2020 Apr; 13(4):403-410. PubMed ID: 32015095 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]